Site-Directed Mutagenesis

Site-Directed Mutagenesis designates molecular biology techniques introducing specific, predetermined changes into DNA sequences at precise locations, enabling targeted amino acid substitutions, insertions, or deletions for protein engineering, functional studies, or understanding structure-function relationships. These methods employ various approaches including oligonucleotide-directed mutagenesis using primers containing desired mutations, PCR-based techniques amplifying mutated sequences, or CRISPR-based genome editing creating targeted genomic changes.

The pharmaceutical industry extensively employs site-directed mutagenesis throughout discovery, development, and manufacturing. Protein engineering uses mutagenesis to improve stability, reduce immunogenicity, enhance binding affinity, or alter enzymatic properties. Antibody optimisation employs CDR mutagenesis to increase affinity through affinity maturation libraries. Fc engineering modifies constant regions, enhancing or reducing effector functions. Structure-function studies introduce mutations probing catalytic mechanisms, identifying critical residues, or validating structural models. Manufacturing cell line optimisation employs mutagenesis to eliminate proteases, modify glycosylation, or enhance productivity. Target validation uses mutagenesis to confirm specific residues mediate drug binding. Regulatory submissions include rationale for engineered changes with comprehensive characterisation demonstrating desired improvements. As computational design improves predictions and high-throughput screening enables rapid evaluation, site-directed mutagenesis applications expand through rational engineering approaches creating next-generation therapeutics with optimised properties.